Annual report pursuant to Section 13 and 15(d)

Fair Value Measurements - Additional Information (Details)

v3.20.4
Fair Value Measurements - Additional Information (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Estimated fair value of equity securities $ 41,644
Unrealized gain (loss) on equity securities 41,498
Vaxcyte, Inc. | Vaxcyte Common Stock  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Estimated fair value of equity securities 41,600
Unrealized gain (loss) on equity securities 41,500
Vaxcyte, Inc. | Vaxcyte Common Stock | Payment Received for Option Exercises and Revaluation of Prior Preferred Stock Warrant Converted to Common Stock  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Unrealized gain (loss) on equity securities 100
Vaxcyte, Inc. | Vaxcyte Common Stock | Revaluation of Estimated Fair Value of Vaxcyte Common Stock  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Unrealized gain (loss) on equity securities $ 41,600
Vaxcyte, Inc. | Equity Securities | Vaxcyte Common Stock  
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]  
Number of shares held | shares 1,567,324